Population Screening

Global Population Screening Market to Reach US$35.3 Billion by 2030

The global market for Population Screening estimated at US$27.2 Billion in the year 2024, is expected to reach US$35.3 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. National Screening, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$25.7 Billion by the end of the analysis period. Growth in the State-wise Screening segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.4 Billion While China is Forecast to Grow at 8.2% CAGR

The Population Screening market in the U.S. is estimated at US$7.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.3 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Population Screening Market – Key Trends & Drivers Summarized

What Is Population Screening and Why Is It Crucial for Public Health?

Population screening is a proactive approach in public health designed to identify diseases, genetic conditions, or risk factors in asymptomatic individuals at an early stage. Unlike diagnostic tests, which confirm a condition in individuals with symptoms, population screening aims to detect health concerns before symptoms develop, allowing for early intervention, improved treatment outcomes, and reduced healthcare costs. Common examples include cancer screening (mammograms, colonoscopies, and HPV tests), newborn screening for metabolic and genetic disorders, cardiovascular risk screening, and infectious disease screening (HIV, hepatitis, and tuberculosis tests).

Governments and healthcare organizations worldwide implement screening programs to reduce disease burden and mortality rates. Mass screening programs have historically been effective in reducing cervical cancer through Pap smears, improving cardiovascular health through lipid profiling, and preventing hereditary conditions through genetic carrier screening. With the increasing prevalence of chronic diseases and age-related conditions, healthcare systems are expanding population screening efforts to cover more conditions, integrate new technologies, and personalize risk assessment based on demographic, genetic, and lifestyle factors.

How Is Technology Revolutionizing Population Screening Methods?

Advancements in medical technology, artificial intelligence (AI), and big data analytics are significantly improving the accuracy, efficiency, and scalability of population screening programs. One of the most transformative developments is the use of AI-powered imaging and machine learning algorithms in radiology and pathology. AI can analyze mammograms, lung scans, and retinal images with higher accuracy than traditional methods, reducing false positives and enabling earlier detection of cancer, diabetic retinopathy, and neurodegenerative diseases.

Another major breakthrough is the rise of liquid biopsy and multi-cancer early detection (MCED) tests, which use blood samples to detect circulating tumor DNA (ctDNA) and other biomarkers indicative of early-stage cancers. These non-invasive tests offer a safer and more convenient alternative to traditional tissue biopsies, making them ideal for large-scale screening programs. Additionally, advancements in genomics and whole-genome sequencing (WGS) have made it possible to screen individuals for inherited diseases, pharmacogenomic responses, and predisposition to complex conditions like Alzheimer`s and diabetes.

The integration of wearable health technology and digital biomarkers is also reshaping how screening is conducted. Devices such as smartwatches, continuous glucose monitors, and ECG-equipped wearables allow for continuous health monitoring, real-time data collection, and early detection of arrhythmias, hypertension, and metabolic disorders. These innovations enable a shift from one-time screening tests to ongoing health surveillance, allowing healthcare providers to intervene at the earliest signs of abnormal physiological changes.

What Are the Key Trends Shaping the Expansion of Population Screening?

One of the most significant trends in population screening is the move toward personalized and risk-based screening protocols. Traditionally, screening guidelines were based on age and broad population criteria, but emerging research in precision medicine and risk stratification is leading to tailored screening recommendations. For example, instead of universal breast cancer screening starting at age 40, genetic risk assessment and family history analysis now help determine whether an individual should start earlier or undergo more frequent screenings. This approach minimizes unnecessary tests while improving outcomes for high-risk individuals.

The expansion of home-based and self-administered screening tests is also driving a shift in healthcare accessibility. The COVID-19 pandemic accelerated the adoption of at-home diagnostic tests, telemedicine consultations, and mail-in sample collection kits, which have since been expanded to HPV, colorectal cancer, and infectious disease screening. These decentralized models allow for higher participation rates, reduced healthcare disparities, and increased convenience, especially for populations in rural areas or those with limited access to medical facilities.

Another growing trend is the integration of population screening into workplace wellness programs and public-private partnerships. Large corporations and insurance providers are now offering preventive health screenings as part of employee benefits, recognizing that early disease detection reduces long-term medical costs and improves workforce productivity. Similarly, public health agencies are collaborating with private biotech firms to develop cost-effective, AI-powered screening solutions that can be deployed at scale. These partnerships help expand access to screening initiatives and optimize public health outcomes.

What Factors Are Driving the Growth of the Population Screening Market?

The growth in the population screening market is driven by several factors, including technological advancements, increased government funding, expanding disease coverage, and the rising prevalence of non-communicable diseases (NCDs). The increasing global burden of chronic diseases such as cancer, cardiovascular disease, and diabetes has heightened the need for proactive disease management through early detection, prompting governments and healthcare organizations to prioritize screening initiatives and allocate larger budgets for preventive care.

Another key driver is the falling costs of genetic sequencing and biomarker analysis, making advanced screening technologies more affordable and accessible. Next-generation sequencing (NGS) and AI-powered diagnostics are now being integrated into routine screening programs, allowing for early identification of genetic predispositions, cancer mutations, and autoimmune markers. This has led to higher adoption rates of genetic and precision screening techniques, particularly in developed healthcare markets such as the United States, Europe, and Japan.

Regulatory initiatives and policy reforms are also fueling the expansion of organized screening programs. Governments worldwide are implementing mandates for cancer screening coverage, newborn screening expansion, and infectious disease testing, ensuring that a larger percentage of the population benefits from early detection services. Additionally, advances in cloud computing and AI-driven data analytics are improving electronic health records (EHR) integration, allowing for better tracking of patient screening histories, risk factors, and follow-up interventions.

Furthermore, the role of consumer-driven healthcare and digital health platforms is reshaping how individuals participate in screening programs. The rise of direct-to-consumer (DTC) health testing companies has empowered individuals to take control of their health by purchasing at-home screening kits and genetic risk assessments without requiring physician referrals. As consumer awareness about preventive healthcare and longevity-focused diagnostics grows, the demand for convenient, technology-enabled screening solutions is expected to continue accelerating worldwide.

SCOPE OF STUDY:

The report analyzes the Population Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Region Type (National Screening, State-wise Screening); Product Type (Hardware Equipment, Testing / Lab Services, Analytics / Interpretation); Screening Type (Mass Screening, Premium Screening); Business Type (Hospitals, Research Institutes, Diagnostic Labs)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Abbott Laboratories
• Aduro
• Agilent Technologies
• ARUP Laboratories
• CHC Wellbeing
• eHealthScreenings
• Empower Health Services
• F. Hoffmann-La Roche Ltd.
• Gene by Gene, Ltd.
• Health Advocate
• Health Designs
• Illumina, Inc.
• LGC Limited
• Novogene Corporation
• Onsite Health Diagnostics
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• US Wellness

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.